Way paved for JV production between Rafarma Pharma and Pharmsynthez

29 January 2014

Rafarma Pharmaceuticals (Pinksheets: RAFA), a Russia-based multi-product pharmaceutical company and St Petersburg-based Pharmsynthez (MICEX: LIFE) have opened discussions for joint venture production.

At meetings initiated by Governor Oleg Korolev of Lipetsk, management from Rafarma and Pharmsynthez have agreed in principal to commence a JV production plan, with the potential to substantially increase revenues for both companies. The agreement is contingent on a satisfactory technical audit of Rafarma's facilities by Pharmsynthez to be conducted next month.

The JV production plan calls for various Pharmsynthez pharmaceutical products to be manufactured in Rafarma's facilities, almost doubling capacity and expanding market share accordingly. The ontological and antibiotic products to be produced currently have domestic revenues of around $250 million. While Pharmsynthez has an existing market share of about 20%, the JV production plan with Rafarma anticipates increasing market share to 35% or more.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK